Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Brooks Macdonald profits slip on acquisition costs

(Sharecast News) - Wealth management firm Brooks Macdonald on Thursday reported a big jump in funds under management and advice (FUMA), though profits slipped year-on-year due to the costs associated with three financial planning acquisitions during the year. Total FUMA increased 17.3% to £19.2bn over the 12 months to30 June, comprising £16.6bn of FUM and advised-only assets of £2.6bn.

Full-year net outflows were £0.4bn, with the second half seeing an improvement as net outflows reduced to just £0.1bn from £0.3bn of outflows in the first half.

Revenues were 4.6% higher at £111.6m, supported by higher financial planning income following the acquisitions of financial planning businesses CST Wealth, Lucas Fettes and LIFT.

However, statutory profit before tax dropped 28.9% to £17.5m due to higher acquisition and integration costs. On an underlying basis, operating profit before tax was still down 4.6% at £28.9m, dragged lower by a fall in the underlying operating profit margin to 25.9% from 28.4%.

Nevertheless, the company declared a final dividend of 51p per share, making a total dividend of 81p, up 3.8% year-on-year.

"This year we have focused on the execution of our strategy to Reignite Growth," said chief executive Andrea Montague.

"We are now a UK-focused wealth manager. We have created a scalable financial planning business. We have launched a suite of Retirement Strategies that meet a growing client need and continue to deliver strong investment performance."

Brooks Macdonald shares rose in early deals, but quick erased gains to trade down 2.1% at 1,781p by 0922 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.